137 related articles for article (PubMed ID: 33559352)
41. Adverse drug and device reactions in the oral cavity: surveillance and reporting.
Zavras AI; Rosenberg GE; Danielson JD; Cartsos VM
J Am Dent Assoc; 2013 Sep; 144(9):1014-21. PubMed ID: 23989840
[TBL] [Abstract][Full Text] [Related]
42. A primer of drug safety surveillance: an industry perspective. Part II: Product labeling and product knowledge.
Allan MC
J Pharm Technol; 1992; 8(5):198-202. PubMed ID: 10171208
[TBL] [Abstract][Full Text] [Related]
43. Data-Driven Identification of Adverse Event Reporting Patterns for Japan in VigiBase, the WHO Global Database of Individual Case Safety Reports.
Wakao R; Taavola H; Sandberg L; Iwasa E; Soejima S; Chandler R; Norén GN
Drug Saf; 2019 Dec; 42(12):1487-1498. PubMed ID: 31559542
[TBL] [Abstract][Full Text] [Related]
44. Effect of database profile variation on drug safety assessment: an analysis of spontaneous adverse event reports of Japanese cases.
Nomura K; Takahashi K; Hinomura Y; Kawaguchi G; Matsushita Y; Marui H; Anzai T; Hashiguchi M; Mochizuki M
Drug Des Devel Ther; 2015; 9():3031-41. PubMed ID: 26109846
[TBL] [Abstract][Full Text] [Related]
45. Timing of Pediatric Drug Approval and Clinical Evidence Submitted to Regulatory Authorities: International Comparison Among Japan, the United States, and the European Union.
Hirota S; Yamaguchi T
Clin Pharmacol Ther; 2020 Nov; 108(5):985-994. PubMed ID: 31869436
[TBL] [Abstract][Full Text] [Related]
46. What Drives Adoption of National Labels as Global Reference Labels? A Case Study With the JPI.
Yoshida S; Matsui R; Kikuchi C
Ther Innov Regul Sci; 2018 Nov; 52(6):724-730. PubMed ID: 29714572
[TBL] [Abstract][Full Text] [Related]
47. Bias in spontaneous reporting of adverse drug reactions in Japan.
Matsuda S; Aoki K; Kawamata T; Kimotsuki T; Kobayashi T; Kuriki H; Nakayama T; Okugawa S; Sugimura Y; Tomita M; Takahashi Y
PLoS One; 2015; 10(5):e0126413. PubMed ID: 25933226
[TBL] [Abstract][Full Text] [Related]
48. Automatic detection of adverse events to predict drug label changes using text and data mining techniques.
Gurulingappa H; Toldo L; Rajput AM; Kors JA; Taweel A; Tayrouz Y
Pharmacoepidemiol Drug Saf; 2013 Nov; 22(11):1189-94. PubMed ID: 23935003
[TBL] [Abstract][Full Text] [Related]
49. Safety and transparency of pediatric drug trials.
Benjamin DK; Smith PB; Sun MJ; Murphy MD; Avant D; Mathis L; Rodriguez W; Califf RM; Li JS
Arch Pediatr Adolesc Med; 2009 Dec; 163(12):1080-6. PubMed ID: 19996043
[TBL] [Abstract][Full Text] [Related]
50. Allergic reactions to Japanese encephalitis vaccine.
Plesner AM
Immunol Allergy Clin North Am; 2003 Nov; 23(4):665-97. PubMed ID: 14753386
[TBL] [Abstract][Full Text] [Related]
51. Traceability of biopharmaceuticals in spontaneous reporting systems: a cross-sectional study in the FDA Adverse Event Reporting System (FAERS) and EudraVigilance databases.
Vermeer NS; Straus SM; Mantel-Teeuwisse AK; Domergue F; Egberts TC; Leufkens HG; De Bruin ML
Drug Saf; 2013 Aug; 36(8):617-25. PubMed ID: 23771794
[TBL] [Abstract][Full Text] [Related]
52. Factors associated with spontaneous reporting of adverse drug reactions in Japan.
Yamada T; Watanabe Y; Kusama M; Sugiyama Y; Ono S
Pharmacoepidemiol Drug Saf; 2013 May; 22(5):468-76. PubMed ID: 23172714
[TBL] [Abstract][Full Text] [Related]
53. An experimental investigation of masking in the US FDA adverse event reporting system database.
Wang HW; Hochberg AM; Pearson RK; Hauben M
Drug Saf; 2010 Dec; 33(12):1117-33. PubMed ID: 21077702
[TBL] [Abstract][Full Text] [Related]
54. Food and Drug Administration monitoring of adverse drug reactions.
Sills JM; Tanner LA; Milstien JB
Am J Hosp Pharm; 1986 Nov; 43(11):2764-70. PubMed ID: 3799612
[TBL] [Abstract][Full Text] [Related]
55. Profiling cumulative proportional reporting ratios of drug-induced liver injury in the FDA Adverse Event Reporting System (FAERS) database.
Brinker AD; Lyndly J; Tonning J; Moeny D; Levine JG; Avigan MI
Drug Saf; 2013 Dec; 36(12):1169-78. PubMed ID: 24178291
[TBL] [Abstract][Full Text] [Related]
56. Impact of a New Consumer Form on the Quantity and Quality of Adverse Event Reports Submitted to the United States Food and Drug Administration.
Muñoz MA; Delcher C; Dal Pan GJ; Kortepeter CM; Wu E; Wei YJ; Xiao H; Winterstein AG
Pharmacotherapy; 2019 Nov; 39(11):1042-1052. PubMed ID: 31479525
[TBL] [Abstract][Full Text] [Related]
57. Packaging and labeling of pharmaceutical products obtained from the internet.
Veronin M
J Med Internet Res; 2011 Feb; 13(1):e22. PubMed ID: 21324833
[TBL] [Abstract][Full Text] [Related]
58. Drug-Associated Acute Kidney Injury Identified in the United States Food and Drug Administration Adverse Event Reporting System Database.
Welch HK; Kellum JA; Kane-Gill SL
Pharmacotherapy; 2018 Aug; 38(8):785-793. PubMed ID: 29883524
[TBL] [Abstract][Full Text] [Related]
59. Digital drug safety surveillance: monitoring pharmaceutical products in twitter.
Freifeld CC; Brownstein JS; Menone CM; Bao W; Filice R; Kass-Hout T; Dasgupta N
Drug Saf; 2014 May; 37(5):343-50. PubMed ID: 24777653
[TBL] [Abstract][Full Text] [Related]
60. FDA postmarketing safety labeling changes: What have we learned since 2010 about impacts on prescribing rates, drug utilization, and treatment outcomes.
Rosenberg M; Sheehan S; Zhou E; Pinnow E; Burnell J; Romine M; Dal Pan G
Pharmacoepidemiol Drug Saf; 2020 Sep; 29(9):1022-1029. PubMed ID: 32790031
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
